INK4D gene were found in samples from ®ve of 67 (7%) patients with osteosarcomas and none were found in other types of sarcomas or in lung cancers. Five osteosarcoma samples had Southern blot patterns consistent with gene rearrangement. These samples included a primary and recurrent osteosarcoma from the same patient; both with the same rearrangement. Four samples had SSCP patterns consistent with sequence alterations, sequencing determined that three were due to silent base changes and apparently polymorphisms. Sequencing the fourth shifted band revealed a one base insertion causing a frameshift beginning with codon 27. In summary, these studies found alterations aecting the p19 INK4D gene in a small but signi®cant number of osteosarcomas. Presumably, abnormalities of this gene contribute to the development of cancer of bone cells.
Introduction
Cell cycle progression from G1 to S phase is regulated by phosphorylation of proteins, including retinoblastoma susceptibility protein (Rb). This phosphorylation is activated by cyclin binding to cyclin dependent kinases (CDK). The activated kinase complexes in turn are inhibited by CDK inhibitors (CDKI) (Hunter and Pines, 1994) . The INK4 family of CDKIs, characterized four ankyrin repeats and activity during G1 to S phase; consists of p15 INK4B (Hannon and Beach, 1994; Guan et al., 1994), p16 INK4A (Serrano et al., 1993; Kamb et al., 1994; Nobori et al., 1994) , p18
INK4C (Guan et al., 1994; Hirai et al., 1995) and p19
INK4D (Hirai et al., 1995; Chan et al., 1995) . All four of the INK4 CDKI inhibit CDK4 and CDK6 complexes with cyclin D which phosphorylate Rb at the junction of G1 and S phase (Serrano et al., 1993; Hannon and Beach, 1994; Guan et al., 1994; Hirai et al., 1995; Chan et al., 1995) .
The G1 to S checkpoint is targetted in neoplastic disease by inactivation of Rb, as well as activation or over-expression of cyclin D1, and CDK4 (Hunter and Pines, 1994) . The same checkpoint is disrupted by alterations of the p16 INK4A gene in certain neoplasms and ell lines derived from a wide variety of tumors (Hirama and Koeer, 1995; Shea and Roberts, 1995; Smith-Sorensen and Hovig, 1996) . Alterations include deletions and point mutations leading to inactivation of p16 (Yang et al., 1995) . The p15
INK4B is frequently deleted with p16
INK4A
, perhaps because the two genes are only 10 ± 15 kilobases apart (Stone et al., 1995) . The p18 INK4C CDKI is apparently rarely aected by structural alterations in either neoplasms or cell lines (Okamoto et al., 1995; Takeuchi et al., 1995; . The fourth member of the ankyrin repeat CDKI family, p19 INK4D , was isolated using the yeast two hybrid system with either Nur77 or CDK4 as bait (Hirai et al., 1995; Chan et al., 1995) . Like the other ankyrin repeat CDKIs, studies demonstrated that p19 INK4D speci®cally inhibited CDK4 and CDK6 (Hirai et al., 1995; Chan et al., 1995) . Over-expression  of transfected p16   INK4A   , p18 INK4C or p19 INK4D decreases clonal growth of cells contingent upon the presence of normal Rb protein (Okamoto et al., 1995; Tam et al., 1994; Guan et al., 1994; Chan et al., 1995) . Two recent studies of mutation of the p19 gene; one detected no changes in any of the samples; the other detected a frameshift alteration in one ovarian cancer cell line (Zariwala and Xiong, 1996; Shiohara et al., 1996) .
Sarcomas are a heterogeneous group of diseases having a variety of histologies. The molecular defects of these diseases are still being de®ned. Activation or rearrangement of oncogenes in sarcomas include the EWS/FC1 translocation in Ewing sarcomas, and the ampli®cation of MDM2 in various sarcomas (Delattre et al., 1992; Momand et al., 1992; Oliner et al., 1992) . Alterations of tumor suppresor genes appear to have a central role in these diseases. Osteosarcomas were the ®rst human cancers found to have alterations of the p53 gene (Masuda et al., 1987) . Furthermore, the Rb gene is frequently altered in osteosarcomas (Friend et al., 1986; Fung et al., 1987) . Alterations of the p16
and p15
INK4B genes occur in fewer than 10% of osteosarcoma tumors but are seen in half of the cell lines .
In non-small lung cancers (NSCL), a heterogenous group of cancers, RAS mutations and overexpression of members of the Myc family are the major changes in oncogenes (Rodenhuis et al., 1988; Johnson et al., 1987) . Alterations of p53 (50 ± 60%) and/or Rb (20 ± 30%) occur in these tumors (Chiba et al., 1990; Xu et al., 1991; Reissman et al., 1993 (Shiohara et al., 1995; Kawamata et al., 1995a,b; Miller et al., 1996) .
To explore for a possible role of p19 INK4D in oncogenesis of these tumors we have looked for structural alterations of the gene by using Southern blotting, single strand conformation polymorphism (SSCP) and DNA sequencing of sarcoma and NSCL cancer samples.
Results

DNA Sequence alterations of the p19 gene in osteosarcomas
Analysis by SSCP was used to detect point mutations, small deletions and insertions of the p19 INK4D gene in DNA from 91 human sarcomas and 34 NSC-lung cancers (Table 1) . Shifts were detected in four sarcoma samples. The SSCP pattern for one of them is shown in Figure 1 . The DNAs from normal human bone marrow (N1) and a sarcome (S3) have normal patterns; S4, an osteosarcoma explant, has one allele with a shifted pattern. The doublestranded form in DNA from S4 (bottom of the Figure) suggests an insertion in the p19 INK4D gene. The upper bands are single stranded forms. The pattern in this sample indicates persistence of one normal copy.
DNA sequencing of S4 indicated a thymidine residue inserted at codon 27 ( Figure 2 ). Sequencing of the DNA from the other three samples with SSCP shifts showed a guanine replacing a cytosine at nucleotide 87 resulting in a silent mutation of codon 29. We suspect that this alteration is a polymorphism, but have not observed it in any of 42 matched normal DNA samples including the 34 NSC-lung cancer samples with matched unaected tissue controls. Furthermore, no alterations were detected in osteosarcoma or lung cancer cell lines.
Rearrangement of the p19 gene in osteosarcomas
Southern blots of EcoRI digested DNA from 57 osteosarcomas, 23 other morphologic types of sarcomas and thirty-four NSC-lung cancer samples with their matched normal tissue were hybridized with a p19 INK4D cDNA (Table 1) . Novel bands were detected in ®ve osteosarcomas: A38, A58, A73, A82 and A117 ( Figure 3a , Table 1 ). The novel EcoRI bands in these samples were between 8 ± 20 kb as compared to the 15 kb fragment detected in human bone marrow and all other samples. No normal sized band was observed in samples A38, A82 and A117 (Figure 3a) . The DNA from samples with rearrangements of the p19 INK4D gene gave normal sized bands with SSCP suggesting that the alterations we have detected lie outside the coding region of the p19 INK4D gene. In osteosarcomas samples A58 and A73 (primary osteosarcoma and recurrent osteosarcoma, respectively from the same patient), both the normal and an aberrant bands were present (Figure 3a and 3b) . Digestion of DNA with Kpn I, which cuts near codon 73 of p19 INK4D , resulted in a 
S3
S4 S5 Figure 1 Single-strand conformational polymorphism (SSCP) for exon 1 of p19 gene. DNA samples were ampli®ed with primers p19F3 and p19R3, yielding a fragment of about 130 basepairs, which was denatured in formamide at 958C, and separated by electrophoresis through 6.5% polyacrylamide TBE gel containing 10% glycerol. After electrophoresis, the gel was exposed to Kodak XOMAT AR ®lm for 12 h. Samples indicated at the origins of the lanes: S3 and S5, osteosarcoma samples with a normal p19 SSCP pattern; S4, a sarcoma with an inserted base in exon 1. The three top bands are single stranded forms, the lowest band is the double-stranded form NL S4
lane order=A G C T Figure 2 Sequence alteration of exon 1 of p19 gene. Shifted bands were excised and directly sequenced. Normal human bone marrow, denoted by NL, shows the normal sequence pattern. The sequence for S4 diers by the presence of an extra thymidine residue 15 kb doublet in normal DNA; in contrast, a Kpn I digest of DNA from the osteosarcoma sample A58 yielded the normal pattern plus a 1.5 kb band ( Figure  3b ). Digestion with PvuII, cutting near codon 127, produced fragments of 2.3 and 1.2 kb in normal DNA and resulted in a novel fragment of 5 kb in the osteosarcoma sample A58 (Figure 3b ). The novel bands in the PvuII and KpnI digests were detected with the 5' speci®c p19 INK4D probe but not the 3' probe (data not shown), suggesting a discontinuity aecting the 5' end of the p19 INK4D gene. Digestion of DNA from osteosarcoma samples A58 and A38 with HindIII produced distinctly sized novel bands; the normal band was about 10 kb; A58 had an extra 20 kb band and A38 had an 8 kb band (data not shown). However, digesting osteosarcoma sample A38 DNA with PvuII revealed no novel bands. Together these results suggest that the rearrangement of the p19 INK4D gene in osteosarcomas appear to be heterogenous.
Discussion
We have found alterations of the p19 INK4D CDKI gene in less than 10% of osteosarcomas. By contrast, no alterations were identi®ed in either the twenty-three samples of other types of sarcomas or the 34 NSC lung cancers. Also, no aberrations of the p19 INK4D gene were detected in eight osteosarcoma and seven NSC-lung cancer cell lines. In other studies, we have found that alterations of the p19 INK4D gene were not features of other neoplasms including hematopoietic neoplasms (n=256), cervical (n=30), breast (n=46) and prostate (n=22) cancers (Park et al., in press; Shiohara et al., 1996) . A frameshift mutation has been reported in one ovarian cell line but in no other sample in a large series of cell lines and tumors (Zariwala and Xiong, 1996) . Thus consistent alteration of p19 INK4D appears to be unique to osteosarcomas.
Alterations of the p19 INK4D gene in osteosarcomas included a frameshift mutation, and ®ve rearrangements. The approach used to detect mutations, SSCP, would be expected to miss 10 ± 20% of base changes, and since the primers were based on cDNA sequences the primers used would only detect 85% of the coding exons. The approach used to detect rearrangements should detect almost any large alteration disrupting the linear order of the p19 INK4D gene. In three samples with p19 INK4D gene rearrangement, only the rearranged allele was detected. The retention of a normal pattern with a rearranged p19 INK4D gene in the remaining samples could be due to either contamination of the tumor with normal cells or persistence of the normal allele. In each case, rearrangement of the p19 INK4D gene was detectable using several dierent restriction digests; therefore, these results are unlikely to represent rare fragment length polymorphisms. Mapping the alterations in two samples shows that the structural changes aect the 5' end of the p19 INK4D can block progression of the cell cycle into S phase (Hirai et al., 1995) . Disruption of p19 INK4D function in osteosarcomas could remove regulation of DNA synthesis in a subset of osteosarcomas. Indirect analysis for tumor suppressor genes at chromosome 19p13, the site of the p19 INK4D gene, infrequently found loss of heterozygosity (LOH) in osteosarcomas (Yamaguchi et al., 1992) . Unfortunately, we lack material to determine if rearrangement of the p19 INK4D gene causes loss of expression or altered expression such as a fusion gene. Continuing studies to de®ne the structure of the p19 INK4D rearrangements may provide clues as to their function.
Rearrangement of the p53 and Rb tumor suppressor genes are not uncommon in human osteosarcomas, but these rearrangements are rare in other tumors (Friend et al., 1986; Fung et al., 1987; Masuda et al., 1987) . Rearrangement of the p53 gene, causing inactivation, occurs most frequently in the ®rst intron of the p53 gene (Miller et al., 1990) .
In summary, we provide evidence that p19 INK4D may be a tumor suppressor, rearrangement or point mutation of the p19 INK4D gene occurs in a signi®cant proportion of human osteosarcoma. Further studies are needed to determine the eect of these arrangements on expression of p19
INK4D
. Primers, PCR, SSCP and sequencing of DNA Primers for amplifying p19 INK4D were based on the cDNA sequence with GenBank accession number U20498 (Hirai et al., 1995) . The ®rst exon of p19 INK4D was ampli®ed with primers p19f3, overlapping codons 1 ± 8, ATGCTGCTG-GAGGAGGTTCGCG, and primer P19R3, overlapping codons 39 ± 46, CTGCAGCGCCGTCTTGCCGAAGCG, yielding a fragment of 141 basepairs. The second exon was analysed as two fragments in order to accommodate for the optimal fragment length for SSCP. The ®rst fragment, exon 2a, was ampli®ed with primers p19f4, covering codons 47 ± 54, GTCATGATGTTTGGCAG-CACCGCC, and p19R7, TGAACTGCCAGATGGATTG-GAAGT, ampli®ed a fragment of 204 basepairs in length. Exon 2b was ampli®ed with primers p19F6, ATTCCTG-GACACCCTGAAGGTCCT, and p19R4, TTCTCTT-GCTGGAGAGGGTGACC, yielding a fragment of 274 basepairs. Because this strategy is based on the cDNA sequences, we can detect alterations of 85% of the codons of the p19 INK4D gene. Oligonucleotides were synthesized by Life Technologies Inc, Gaithersberg, Maryland. Polymerase chain reaction was performed using 100 ng DNA, 0.2 mM dNTP, 1.5 mM MgCl 2 , Taq polymerase (Life Technologies Inc, Gaithersberg, MD) in the reaction buer provided by the supplier. Samples were labeled by the addition of 1 Ci[ 32 P]-dCTP to each sample. Thermal cycler parameters were 958C for 30 s, 558C for 30 s and 728C for 60 s for 35 cycles.
Materials and methods
Samples
Electrophoresis for SSCP analysis was performed as previously described . Shifted bands, and bands from normal controls were excised from dried acrylamide gels, suspended in water and re-ampli®ed for direct sequencing of DNA (Miller et al., 1990) . Direct sequencing with 32 P end-labeled primers used the Cycle Sequencing Kit from Gibco-BRL (Life Technologies Inc, Gaithersberg, MD).
Southern blotting
Sucient, intact DNA was available for 148 samples from 106 patients for analysis by Southern blotting. Samples included 34 lung cancers with matched DNA controls. Five to ten g of each sample, digested with 50 units of EcoRI for 2 h, was separated on 1% Agarose gels at 50 volts. The gels were transferred to Biotrans nylon membrane and hybridized. Overnight hybridization at 428C was performed using 5610 6 DPM/ml 32 P-labeled probe; and the ®nal rinse of the blots was 0.16SSC at 658C (Miller et al., 1990) . The EcoRI blots were probed with a full length p19 INK4D cDNA excised from pSPhp19 using EcoRI (kind gift of A Winoto) (Chan et al., 1995) . The insert was cut at codon 127 with PvuII to provide a 5' probe (p19S) and a 3' probe (p19L), which were used for mapping rearrangements. The quality and quantity of DNA was checked by hybridizing with a probe for myeloperoxidase (Johnson et al., 1985) .
